Payment overview · 2025
General Payments
$772.60
42 reported records · 8 companies
Healthcare provider profile · identity verified
Gigi E Baker, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MO · NPI 1184666117
Verified facts
What the public records show
CMS Open Payments records show Gigi E Baker, MD received $772.60 in general payments during 2025 across 42 reported records.
Abbott Laboratories accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $185.17 | 24.0% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $179.83 | 23.3% | 12 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $148.69 | 19.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.18 | 14.8% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.84 | 8.0% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $44.42 | 5.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.14 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.33 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $772.60 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $185.17 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $148.69 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $126.77 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.18 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.25 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $53.06 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.27 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
68 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 582 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 526 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 520 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 105 |
| Losartan Potassium | Losartan Potassium | 371 | 91 |
| Lisinopril | Lisinopril | 333 | 85 |
| Omeprazole | Omeprazole | 306 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 280 | 73 |
| Gabapentin | Gabapentin | 220 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 53 |
| Alendronate Sodium | Alendronate Sodium | 186 | 52 |
| Eliquis | Apixaban | 177 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 40 |
| Simvastatin | Simvastatin | 154 | 44 |
| Trazodone Hcl | Trazodone Hcl | 149 | 41 |
| Tramadol Hcl | Tramadol Hcl | 141 | 32 |
| Potassium Chloride | Potassium Chloride | 135 | 36 |
| Famotidine | Famotidine | 124 | 40 |
| Metformin Hcl | Metformin Hcl | 124 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 35 |
| Furosemide | Furosemide | 117 | 32 |
| Sertraline Hcl | Sertraline Hcl | 117 | 33 |
| Carvedilol | Carvedilol | 116 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 39 |
| Ozempic | Semaglutide | 112 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 27 |
| Meloxicam | Meloxicam | 107 | 29 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 100 | 100 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 24 |
| Allopurinol | Allopurinol | 89 | 22 |
| Montelukast Sodium | Montelukast Sodium | 89 | 22 |
| Estradiol | Estradiol | 87 | 25 |
| Ezetimibe | Ezetimibe | 86 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 22 |
| Memantine Hcl | Memantine Hcl | 82 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 28 |
| Prednisone | Prednisone | 80 | 55 |
| Alprazolam | Alprazolam | 77 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 75 | 75 |
| Buspirone Hcl | Buspirone Hcl | 72 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 68 | 68 |
| Metformin Hcl Er | Metformin Hcl | 66 | 22 |
| Synthroid | Levothyroxine Sodium | 65 | 15 |
| Enalapril Maleate | Enalapril Maleate | 63 | 14 |
| Donepezil Hcl | Donepezil Hcl | 60 | 15 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Celecoxib | Celecoxib | 56 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 18 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Pregabalin | Pregabalin | 51 | 11 |
| Atenolol | Atenolol | 48 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 44 |
| Lovastatin | Lovastatin | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Primidone | Primidone | 38 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Nystatin | Nystatin | 34 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 29 |
| Bupropion Hcl | Bupropion Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | 11 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Ramipril | Ramipril | 31 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 23 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Prempro | Estrogen,con/M-Progest Acet | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Clonidine | Clonidine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $772.60 · 42 records | Abbott Laboratories | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FABRAZYME, FARXIGA, FREESTYLE LIBRE, INSPIRE, KISUNLA, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error